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Abstract
Background: It is important to understand the consequences of pre-emptive antibiotic treatment in neonates, as
disturbances in microbiota development during this key developmental time window might affect early and later
life health outcomes. Despite increasing knowledge regarding the detrimental effect of antibiotics on the gut
microbiota, limited research focussed on antibiotic treatment duration. We determined the effect of short and long
amoxicillin/ceftazidime administration on gut microbiota development during the immediate postnatal life of
preterm and term infants.
Methods: Faeces was collected from 63 (pre) term infants at postnatal weeks one, two, three, four and six. Infants
received either no (control), short-term (ST) or long-term (LT) postpartum amoxicillin/ceftazidime treatment.
Results: Compared to control infants, ST and LT infants’ microbiota contained significantly higher abundance of
Enterococcus during the first two postnatal weeks at the expense of Bifidobacterium and Streptococcus. Short and
long antibiotic treatment both allowed for microbiota restoration within the first six postnatal weeks. However,
Enterococcus and Bifidobacterium abundances were affected in fewer ST than LT infants.
Conclusions: Intravenous amoxicillin/ceftazidime administration affects intestinal microbiota composition by decreasing
the relative abundance of Escherichia-Shigella and Streptococcus, while increasing the relative abundance of Enterococcus
and Lactobacillus species during the first two postnatal weeks. Thriving of enterococci at the expense of bifidobacteria
and streptococci should be considered as aspect of the cost-benefit determination for antibiotic prescription.
Keywords: Gut microbiota, Preterm, Infant, Antibiotics, Next generation sequencing
Background
Neonatal infections are a major cause of mortality and
morbidity, especially in preterm infants [1, 2]. Since
symptoms of infection are mostly non-specific and infec-
tion can rapidly progress, most preterm infants are
treated with broad-spectrum antibiotics before diagnosis.
This, however, could result in overtreatment and
increased risk of selection for resistant bacteria [3]. To re-
duce antibiotic use, the need for further antibiotic treat-
ment is evaluated after 36–48 h. In addition to increasing
the risk of antibiotic resistance, antibiotics might interfere
with the development of the intestinal microbiota. During
birth and thereafter, microbes rapidly colonise the human
gastrointestinal tract. This process is not yet completely
understood as it is highly dynamic and influenced by mul-
tiple host and environmental factors [4]. An abnormal pat-
tern of bacterial colonisation has been observed in
preterm infants compared to term infants, associated with
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greater exposure to factors like caesarean section, hospi-
talisation, formula feeding and antibiotic treatment [5, 6].
Gut microbiota development coincides with, and influ-
ences, development of the gastrointestinal tract and im-
mune system. Disturbances in early life microbiota
development could therefore affect early and later life
health outcomes [7, 8]. Previous studies showed that the
intestinal microbiota of preterm infants is affected by anti-
biotic treatment and characterised by high levels of facul-
tative anaerobic bacteria and delayed colonisation with
obligate anaerobes like Bifidobacterium [9–11]. The use of
antibiotics in early-life, and corresponding disturbances of
the gut microbiota, have been associated with negative
health outcomes, including asthma, atopy and obesity
[12–14]. Despite increasing knowledge about the effect of
antibiotics on the microbiota, limited research focussed
on antibiotic treatment duration [15–17]. We determined
the effect of short-term and long-term postpartum anti-
biotic treatment on the gut microbiota throughout the
first six postnatal weeks in 63 infants. Herein, the primary
outcome was defined as the effect of antibiotic treatment
duration on microbiota composition. As secondary out-
come, the effect of other parameters on microbiota com-
position were studied, including gestational age, delivery
mode, maternal antibiotics, enteral feeding tolerance, feed-
ing type and respiratory support.
Methods
Subjects and sample collection
This study was part of an observational, single-centre,
non-intervention study involving (pre) term infants ad-
mitted to the hospital level III neonatal intensive care
unit or level II neonatal ward of Isala in Zwolle, The
Netherlands. Infants born between 32 and 42 weeks ges-
tation, admitted to the level II neonatal ward without
major congenital malformation or malformations of the
gastrointestinal tract, were eligible for inclusion. In-
formed consent was obtained from both parents of all
individual participants. A total of 125 infants were eli-
gible, of which seven infants were excluded due to
incompliance, 40 infants were excluded due to incom-
plete longitudinal sampling or insufficient sample quan-
tity, and 15 infants were previously included in a pilot
study, resulting in 63 infants for inclusion. Infants were
fed own mother’s milk, which was supplemented with
(preterm) infant formula containing GOS/FOS when
needed. Infants received either no (control, n = 28),
short-term (< 3 days, ST, n = 22) or long-term (> 5 days,
LT, n = 13) treatment with amoxicillin/ceftazidime (100
mg/kg/day amoxicillin / 100mg/kg/day ceftazidime di-
vided over two doses) during the first postnatal week.
Antibiotic treatment started at the day of birth on the
clinical suspicion of early-onset neonatal sepsis accord-
ing to the hospital protocol (maternal risk factors as
chorioamnionitis, fever, elevated infection parameters,
Group B Streptococcus-carrier, preterm premature rup-
ture of membranes < 35 weeks gestation, unexplained
preterm birth with respiratory distress, clinical symp-
toms of sepsis or meningitis, need for artificial ventila-
tion) and judgement by the attending physician. After
48 h, the need of antibiotic treatment was evaluated
based on clinical signs, blood culture and serial C-
reactive protein. Faecal samples were collected at post-
natal weeks one, two, three, four and six, resulting in
263 samples, which were stored at − 20 °C until transfer
to − 80 °C. Infant demographics are shown in Table 1.
16S rRNA gene amplicon sequencing
DNA extraction, library preparation and sequencing
were performed by LifeSequencing S.L. (Valencia, Spain).
DNA was extracted from 200mg faeces using the
QIAamp Fast DNA Stool Mini Kit (Qiagen), including
cell disruption by bead beating. DNA was purified and
concentrated using the PowerMag DNA clean-up kit
(MoBio) and 50 ng of DNA was amplified according to
the Metagenomic Sequencing Library Illumina 15,044,
223 B protocol (Illumina) using 16S rRNA gene primers
for region V3-V4 [18]. Libraries were quantified using
the Quant-iT™ PicoGreen™ dsDNA Assay Kit (Thermo-
fisher) and pooled prior to sequencing on the MiSeq
platform (Illumina, 300 bases, paired-end).
Data analysis
Read filtering, operational taxonomic unit (OTU)-pick-
ing and taxonomic assignment were performed using
the NG-Tax pipeline with following settings: read length
of 70, ratio OTU abundance of 2, classify ratio of 0.8,
minimum percentage threshold of 0.5, identity level of
100%, error correction of 98.5, using the Silva 128 data-
base [19, 20]. Coordinate analysis and differential abun-
dance testing were performed in R (v3.6.1) using the
packages phyloseq (v1.30.0), DESeq2 (v1.26.0), ggpubr
(v0.2.4), microbiome (v1.8.0) and vegan (v2.5–6). To cor-
relate the relative abundance of bacterial taxa with each
other, Spearman’s rank correlation coefficient was deter-
mined. Prior differential abundance testing and correl-
ation analysis, bacterial genera present in less than 25%
of samples were removed to minimise zero-variance
errors and spurious significance. For within infant
(dependent) or between infants (independent) compari-
sons, the nonparametric Wilcoxon Signed Rank test and
Kruskal-Wallis test were applied, respectively. To relate
microbiota composition to clinical data, redundancy
analysis (RDA) was performed using Canoco multivari-
ate statistics software v5. Clinical factors included in the
analysis are shown in Additional file 2 and were consid-
ered to have a significant influence on microbiota
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composition when the false discovery rate (FDR) cor-
rected p-value was below 0.05.
Results
Differences in gut microbiota composition between
infants receiving no, short or long antibiotic treatment
Faecal microbiota composition was determined during the
first six postnatal weeks in moderate- to late-preterm and
term infants (32–42 weeks gestation) receiving either no
(control), short-term (ST) or long-term (LT) antibiotic
treatment during the first postnatal week (Fig. 1). Overall
microbiota composition was significantly associated with
antibiotic treatment duration during the first three postna-
tal weeks, but not at postnatal weeks four and six (Add-
itional file 1). Differential abundance testing revealed that,
at the first postnatal week, ST and LT infants’ microbiota
contained significantly lower relative abundance of Escher-
ichia-Shigella (Log2FoldChange = − 7.498, p = 0.0003;
Log2FoldChange = − 5.442, p = 0.008, respectively) and
Streptococcus (Log2FoldChange = − 4.011, p = 0.027;
Log2FoldChange = − 3.795, p = 0.018, respectively), while
higher abundance of Lactobacillus (Log2FoldChange =
27.979, p = 3.11 × 10− 21; Log2FoldChange = 6.743, p =
0.030, respectively) as compared to control infants. In LT
infants, higher relative abundance of Enterococcus was ob-
served at the second postnatal week, as compared to con-
trol infants (Log2FoldChange = 2.996, p = 0.005).
A comparison between ST and LT infants revealed sig-
nificantly higher relative abundance of Clostridium sensu
stricto 1 (Log2FoldChange = 21.783, p = 2.63 × 10− 12) and
lower abundance of Veillonella (Log2FoldChange = −
26.954, p = 2.05 × 10− 18) at the first postnatal week. During
the first two postnatal weeks, Enterococcus became an
abundant member of the community in a higher percent-
age of LT than ST infants (Fig. 2). In addition, Bifidobacter-
ium was an abundant community member in a higher
Table 1 Patient demographics
Control ST LT
Infants n 28 22 13
Gestational age (weeks) 34.8 ± 1.4 34.2 ± 2.2 37.2 ± 3.1
Birthweight (gram) 2309 ± 456 2406 ± 588 3111 ± 863
Vaginal birth 13 (46.4%) 15 (68.2%) 6 (46.2%)
Male 13 (46.4%) 13 (59.1%) 8 (61.5%)
Preterm 24 (85.7%) 19 (86.4%) 7 (53.8%)
Twin 11 (39.3%) 5 (22.7%) 2 (15.4%)
AB treatment (days) 0 2.2 ± 0.5 7.5 ± 2.2
CPAP 5 (17.9%) 10 (45.5%) 0 (0%)
Food intolerant 0 (0%) 0 (0%) 1 (7.7%)
TPN 2 (7.1%) 0 (0%) 1 (7.7%)
Days until FEF 7.0 ± 1.0 7.2 ± 1.3 7.6 ± 0.9
HM> 50% throughout 6 PNW 19 (67.9%) 15 (68.2%) 7 (53.8%)
% HM throughout 6 PNW 68 ± 27 71 ± 34 63 ± 32
Cause of infection:
Proven sepsis 3 (23.1%)
Clinical sepsis 6 (46.2%)
Pneumonia 3 (23.1%)
Meningitis 1 (7.7%)
Causative pathogen:
Group B Streptococcus 4 (30.8%)
Escherichia coli 1 (7.7%)
Unknown 8 (61.5%)
Mothers Preeclampsia 5 (17.9%) 3 (13.6%) 2 (15.4%)
PROM 5 (17.9%) 5 (22.7%) 6 (46.2%)
AB around birth 19 (67.9%) 15 (68.2%) 9 (69.2%)
AB > 48 h after birth 2 (7.1%) 3 (13.6%) 4 (30.8%)
Abbreviations: AB: antibiotics, CPAP: continuous positive airway pressure, TPN: total parenteral nutrition, FEF: full enteral feeding, HM: human milk, PNW: postnatal
week, PROM: prolonged rupture of membranes
Zwittink et al. BMC Pediatrics          (2020) 20:195 Page 3 of 10
percentage of ST than LT infants at postnatal weeks four
and six (Fig. 2).
Community richness and diversity were not consist-
ently affected by antibiotic treatment. Instead, commu-
nity richness and diversity related to which taxa
dominated the community. In mixed communities and
communities in which Bifidobacterium was abundant,
richness and diversity were higher than when either
Enterococcus, Streptococcus or Staphylococcus was abun-
dant, with lowest richness and diversity being observed
for Enterococcus (Additional file 4).
Gut microbiota succession in infants receiving no, short
or long antibiotic treatment
The bacterial genera Bifidobacterium, Streptococcus,
Enterococcus, Staphylococcus, Escherichia-Shigella and
Fig. 1 Microbiota composition profiles in control, ST and LT infants during the first six postnatal weeks, with a focus on Bifidobacterium and
Enterococcus. Bar graphs: Average relative abundances per time point are shown. Line graphs: Mean ± 95% confidence interval are shown
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members of the Enterobacteriaceae family made up the
biggest proportion of the (pre) term infant faecal
microbiota (Fig. 1). Relative abundance of Enterobacte-
riaceae negatively correlated with abundance of Escher-
ichia-Shigella (ρ = − 0.275, p = 4.0 × 10− 6). Enterococcus
abundance negatively correlated with Bifidobacterium
(ρ = − 0.260, p = 1.3 × 10− 5) and Streptococcus (ρ = −
0.279, p = 3 × 10− 6).
In control infants, the intestinal microbiota was
characterised by high relative abundance of Bifidobac-
terium, Streptococcus, Enterococcus, Staphylococcus,
Escherichia-Shigella and members of the Enterobacte-
riaceae family (Fig. 1). During the first six postnatal
weeks, a trend of increasing relative abundance of Lacto-
bacillus (Log2FoldChange = 5.075, p = 0.082) and decreas-
ing Staphylococcus (Log2FoldChange = − 4.996, p = 0.084)
was observed.
The intestinal microbiota of infants receiving short-
term antibiotic treatment was characterised by high
relative abundance of Bifidobacterium, Enterococcus,
Staphylococcus, Streptococcus, Escherichia-Shigella,
Clostridium and members of the Enterobacteriaceae
family (Fig. 1). During the first six postnatal weeks,
relative abundance of Streptococcus significantly increased
(Log2FoldChange = 7.112, p = 0.015), and a trend of in-
creasing relative abundance of Bifidobacterium (Log2Fold-
Change = 4.820, p = 0.098) was observed.
The intestinal microbiota of infants receiving long-term
antibiotic treatment was characterised by high relative
abundance of Bifidobacterium, Enterococcus, Clostridium,
Staphylococcus, Escherichia-Shigella, Bacteroides and
members of the Enterobacteriaceae family (Fig. 1). Over
time, a trend of increasing Streptococcus (Log2Fold-
Change = 5.705, p = 0.050) was observed.
Bacterial richness and diversity generally increased
over time in all infants, independent of antibiotic treat-
ment duration (Fig. 3).
Clinical variables associated with microbiota composition
during the first six postnatal weeks
The effect of various clinical characteristics on micro-
biota composition was determined by redundancy ana-
lysis. Clinical variables explaining variation in microbiota
composition were group-specific, and included delivery
mode, feeding-related factors and postnatal age (Table 2).
When combining the three groups, antibiotic treatment
duration explained 2.5% of variation in microbiota com-
position between samples (Table 2). In addition, postna-
tal age (5.5%), gender (2.9%), days until full enteral
feeding (2.2%), delivery mode (2.0%) and gestational age
(1.5%) affected microbiota composition (Table 2). Males
were associated with increased abundance of Escheri-
chia-Shigella, while females were associated with in-
creased abundance of other members of the
Enterobacteriaceae family (Additional file 3). This differ-
ence was statistically significant at postnatal weeks two,
three and four (p < 0.05). Increased postnatal age, no
antibiotic treatment, less days until full enteral feeding
and higher gestational age were associated with in-
creased abundance of Bifidobacterium (Additional file
3). Regarding gestational age, this study comprised pre-
term and term infants. The intestinal microbiota of term
and preterm infants responded to antibiotic treatment in
a similar manner (Additional file 5). On average, Bifido-
bacterium abundance was higher in term compared to
preterm infants, however, this was not statistically
significant.
Discussion
Intravenous antibiotic administration for prevention and
treatment of infection and sepsis occurs frequently in
neonatal units. Therefore, it is of great relevance to
study side effects of antibiotic treatment, including its ef-
fect on gut microbiota development. We studied the ef-
fect of postpartum antibiotic treatment duration on
Fig. 2 Fraction of infants in which Bifidobacterium (a) or Enterococcus (b) was an abundant member of the bacterial community. An abundant
member was defined as a relative abundance of ≥10%
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microbiota development in 63 (pre) term infants during
the first six postnatal weeks.
The genera Bifidobacterium, Streptococcus, Entero-
coccus, Staphylococcus, Escherichia-Shigella and mem-
bers of the Enterobacteriaceae family made up the
biggest proportion of the (pre) term infant faecal micro-
biota. Relative abundances of Enterococcus and Staphylo-
coccus decreased during the first six postnatal weeks,
while abundances of Streptococcus and Bifidobacterium
increased. Overall microbiota composition was associ-
ated with antibiotic treatment duration during the first
three postnatal weeks. Short- and long-term antibiotic
treatment with amoxicillin/ceftazidime affected micro-
biota composition by decreasing the relative abundance
of Escherichia-Shigella and Streptococcus, while increas-
ing the relative abundance of Enterococcus and Lactoba-
cillus species, which is in concordance with our previous
findings [17]. Ceftazidime and amoxicillin are broad-
spectrum β-lactam antibiotics, targeting Gram-positive
and -negative bacteria. It has been shown that Bifidobac-
terium species are sensitive to β-lactam antibiotics and
that treatment with amoxicillin can greatly influence the
composition of Bifidobacterium species in infant intes-
tinal microbiota [21–23]. As such, establishment of a
Bifidobacterium-dominated microbiota can be delayed
or prohibited. Strikingly, relative abundance of Entero-
coccus increased after long-term antibiotic treatment,
which might indicate antibiotic resistance, as it is a tar-
get organism of amoxicillin. As some Enterococcus spe-
cies emerged from gut commensals to nosocomial
pathogens, this might pose a health risk for the infants
[24]. Indeed, Enterococcus species have been identified as
causative organism in late-onset sepsis [25, 26]. How-
ever, the applied methodology herein cannot reliably
identify Enterococcus to species level, and whether abso-
lute abundances of Enterococcus increased has not been
elucidated in the study herein.
Few differences in microbiota composition were ob-
served between infants receiving short- or long-term
antibiotic treatment. However, its noteworthy that En-
terococcus became an abundant community member in a
higher percentage of long- than short-treated infants. As
well, Bifidobacterium did not become an abundant com-
munity member in a higher percentage of long- than
short-treated infants. This indicates that long antibiotic
treatment has a more profound effect on microbiota de-
velopment than short treatment, similar to what we have
previously reported [17]. High inter-individual variation,
in combination with the relatively small number of long-
treated infants, most certainly decreased statistical
power. In addition, inclusion of all infants, instead of
studying a carefully selected subset, did not allow to pre-
vent possible bias by parameters like gestational age, de-
livery mode, gender, maternal antibiotics and feeding.
Fig. 3 Community richness and diversity during the first six postnatal weeks in control (a), ST (b) and LT (c) infants. Boxplots show the median,
25th and 75th percentiles, and minimal and maximal values with the exception of outliers (circles) and extremes (asterisks). Differences in richness
and diversity between time points were determined using the Wilcoxon Signed Rank test with Monte Carlo permutation
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For example, 46.2% of long-treated infants were born at
term, while only 13.6% of short-treated infants were
born at term. Nevertheless, stratification of infants based
on preterm and term birth indicated similar response to
antibiotic treatment.
Community richness and diversity were not consist-
ently affected by antibiotic treatment. Instead, richness
and diversity increased over time, and were related to
which bacterial taxon was abundant. Richness and diver-
sity were lower when either Enterococcus, Streptococcus
or Staphylococcus was abundant, and higher when other
bacterial taxa, including Bifidobacterium, were abundant.
As the relative abundance of Bifidobacterium increased
over time, postnatal age and Bifidobacterium abundance
were related, hindering the elucidation of their sole ef-
fect on community richness and diversity.
In addition to antibiotic treatment duration, micro-
biota composition was associated with postnatal age,
gender, days until full enteral feeding, delivery mode and
gestational age. Increased gestational and postnatal age
and less days until full enteral feeding were associated
with higher abundance of early life coloniser Bifidobac-
terium. A Bifidobacterium-dominated microbiota is
more representative of microbiota development in term,
vaginally born, breast-fed infants, which is considered
most beneficial during early life development [27]. The
beneficial effect of Bifidobacterium species is speculated
to be obtained by providing protection against pathogens
and via its immune modulating properties [28]. Since
dominance by Bifidobacterium, compared to other bac-
terial taxa, allowed for higher community richness and
diversity, we speculate that Bifidobacterium species con-
trol, but not outcompete, other bacterial species. Bifido-
bacteria could therefore play an important role in
development of a healthy and diverse ecosystem that
promotes tolerance induction and immune system mat-
uration. In addition, bifidobacteria are optimal milk de-
graders, and known for their role in degradation of
simple and complex sugars like human milk oligosaccha-
rides [29]. Early differences in microbiota composition
may therefore affect an infants’ food digestion capacity
and subsequent energy harvest [30, 31]. This is particu-
larly relevant for preterm born infants with protein and
energy deficits [32, 33]. Regarding gender, males micro-
biota contained higher abundance of Escherichia-Shi-
gella, while the microbiota of females contained more
members of the Enterobacteriaceae family that could not
be classified to genus level. Several studies have shown
that gut microbiota composition differs between adult
males and females [34, 35], but gender-effect during
early life is relatively unexplored [36]. It is important to
note that while many clinical variables were included in
the analysis, they did not capture the full extent of
microbiota variation observed between samples. As such,
unknown determinants affecting microbiota composition
in (pre) term infants remain.
Conclusions
Our findings show that intravenous administration of
amoxicillin/ceftazidime affects intestinal microbiota
composition, particularly by decreasing the relative
abundance of Escherichia-Shigella and Streptococcus,
while increasing the relative abundance of Lactobacillus
and Enterococcus species during the first two postnatal
weeks. Short and long antibiotic treatment both allow
for intestinal microbiota restoration within the first six
postnatal weeks as characterised by increasing relative
abundance of Bifidobacterium species. Long treatment,
however, potentially has more enduring effect on micro-
biota development than short treatment, but this needs
to be further elucidated. Although being of short-term,
the rise of enterococci at expense of bifidobacteria and
streptococci, including the potential effect of disturbed
microbiota development on health outcomes, should be
considered as aspect of the cost-benefit determination
for antibiotic prescription.
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Additional file 1. Principal Coordinate Analysis (PCoA) plots using Bray-
Curtis distances. The association of microbiota composition with postna-
tal week (WoL) or antibiotic treatment duration (AB1_dur) was assessed
by Permutational multivariate analysis of variance (PERMANOVA) using
the ‘adonis’ function with 999 permutations
Additional file 2. Clinical factors included during redundancy analysis
(RDA)
Additional file 3. Redundancy analysis using microbiota composition
profiles from (A) control infants and (B) all infants. Species with a 15-
100% fit into the ordination space and explanatory variables that signifi-
cantly explain variation are shown. Abbreviations: C-section: caesarean
section, AB: antibiotics, FEF: full enteral feeding, PNW: postnatal weeks.
Additional file 4. Richness and diversity in samples with different
dominating bacterial taxa. Taxa were considered dominant in a sample
when it was the most abundant taxon and at least 10% more abundant
than the second most abundant taxon. When the difference between
the two most abundant taxa was less than 10%, is was considered a
mixed community. Boxplots show the median, 25th and 75th percentiles,
and minimal and maximal values with the exception of outliers (circles)
and extremes (asterisks). Lines above the graph indicate between which
communities a significant difference in richness/diversity was observed
Additional file 5.. Microbiota composition profiles during the first six
postnatal weeks in preterm and term infants receiving no, short or long
antibiotic treatment. Average relative abundances per time point are
shown.
Abbreviations
FDR: False discovery rate; OTU: Operational taxonomic unit;
RDA: Redundancy analysis; ST: Short-term; LT: Long-term
Acknowledgements
Not applicable.
Zwittink et al. BMC Pediatrics          (2020) 20:195 Page 8 of 10
Authors’ contributions
RDZ: Experimental design, data acquisition, data analysis, interpretation of
findings, manuscript preparation. DvZ: Study design, sample acquisition,
interpretation of findings, manuscript revision. IBR: Interpretation of findings,
manuscript revision. RAvL: Study design, sample acquisition, interpretation of
findings, manuscript revision. OFN: Study design, sample acquisition, revision
of manuscript. RM: Study design, revision of manuscript. LJGJ: Sample
acquisition, revision of manuscript. JK: Study design, experimental design,
interpretation of findings, revision of manuscript. CB: Experimental design,
interpretation of findings, revision of manuscript. The author(s) read and
approved the final manuscript.
Funding
Not applicable.
Availability of data and materials
Raw sequencing data and supporting metadata are available in the
European Nucleotide Archive (http://www.ebi.ac.uk/ena) under study
accession PRJEB26802.
Ethics approval and consent to participate
The board from the Medical Ethical Committee of Isala Zwolle concluded
that this study does not fall under the scope of the Medical Research
Involving Human Subjects Act (WMO). Written informed consent was
obtained from both parents of all individual participants included in the
study.
Consent for publication
Not applicable.
Competing interests
The authors IBR, RM and JK are employees of Danone Nutricia Research. The
authors RDZ and CB were financially supported by Danone Nutricia
Research.
Author details
1Laboratory of Microbiology, Wageningen University, Stippeneng 4, 6708WE,
Wageningen, The Netherlands. 2Princess Amalia Dpt of Paediatrics, Dpt of
Neonatology, Isala, Zwolle, The Netherlands. 3Danone Nutricia Research,
Utrecht, The Netherlands.
Received: 18 December 2018 Accepted: 1 April 2020
References
1. Khan AM, Morris SK, Bhutta ZA. Neonatal and perinatal infections. Pediatr
Clin N Am. 2017;64(4):785–98.
2. Shane AL, Sanchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390(10104):
1770–80.
3. Schulman J, Dimand RJ, Lee HC, Duenas GV, Bennett MV, Gould JB.
Neonatal intensive care unit antibiotic use. Pediatrics. 2015;135(5):826–33.
4. Rodriguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, et al. The
composition of the gut microbiota throughout life, with an emphasis on
early life. Microb Ecol Health Dis. 2015;26:26050.
5. Forsgren M, Isolauri E, Salminen S, Rautava S. Late preterm birth has direct
and indirect effects on infant gut microbiota development during the first
six months of life. Acta Paediatr. 2017;106(7):1103–9.
6. Gregory KE, Samuel BS, Houghteling P, Shan G, Ausubel FM, Sadreyev RI,
et al. Influence of maternal breast milk ingestion on acquisition of the
intestinal microbiome in preterm infants. Microbiome. 2016;4(1):68.
7. Clarke G, O'Mahony SM, Dinan TG, Cryan JF. Priming for health: gut
microbiota acquired in early life regulates physiology, brain and behaviour.
Acta Paediatr. 2014;103(8):812–9.
8. Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and
disease. Cell Host Microbe. 2015;17(5):553–64.
9. Arboleya S, Sanchez B, Milani C, Duranti S, Solis G, Fernandez N, et al.
Intestinal microbiota development in preterm neonates and effect of
perinatal antibiotics. J Pediatr. 2015;166(3):538–44.
10. Gibson MK, Crofts TS, Dantas G. Antibiotics and the developing infant gut
microbiota and resistome. Curr Opin Microbiol. 2015;27:51–6.
11. Zwittink RD, van Zoeren-Grobben D, Martin R, van Lingen RA, Groot Jebbink
LJ, Boeren S, et al. Metaproteomics reveals functional differences in
intestinal microbiota development of preterm infants. Mol Cell Proteomics.
2017;16(9):1610–20.
12. Korpela K, Salonen A, Virta LJ, Kekkonen RA, Forslund K, Bork P, et al.
Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-
school children. Nat Commun. 2016;7:10410.
13. Rasmussen SH, Shrestha S, Bjerregaard LG, Angquist LH, Baker JL, Jess T,
et al. Antibiotic exposure in early life and childhood overweight and
obesity: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;
20(6):1508–14.
14. Wopereis H, Sim K, Shaw A, Warner JO, Knol J, Kroll JS. Intestinal microbiota
in infants at high risk for allergy: effects of prebiotics and role in eczema
development. J Allergy Clin Immunol. 2018;141(4):1334–42 e5.
15. Dardas M, Gill SR, Grier A, Pryhuber GS, Gill AL, Lee YH, et al. The impact of
postnatal antibiotics on the preterm intestinal microbiome. Pediatr Res.
2014;76(2):150–8.
16. Greenwood C, Morrow AL, Lagomarcino AJ, Altaye M, Taft DH, Yu Z, et al.
Early empiric antibiotic use in preterm infants is associated with lower
bacterial diversity and higher relative abundance of Enterobacter. J Pediatr.
2014;165(1):23–9.
17. Zwittink RD, Renes IB, van Lingen RA, van Zoeren-Grobben D, Konstanti P,
Norbruis OF, Martin R, Groot Jebbink LJM, Knol J, Belzer C. Association
between duration of intravenous antibiotic administration and early-life
microbiota development in late-preterm infants. Eur J Clin Microbiol Infect
Dis. 2018;37(3):475–83. https://doi.org/10.1007/s10096-018-3193-y. Epub
2018 Jan 24.
18. Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M, et al.
Evaluation of general 16S ribosomal RNA gene PCR primers for classical and
next-generation sequencing-based diversity studies. Nucleic Acids Res. 2013;
41(1):e1.
19. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA
ribosomal RNA gene database project: improved data processing and web-
based tools. Nucleic Acids Res. 2013;41(Database issue):D590–6.
20. Ramiro-Garcia J, Hermes GDA, Giatsis C et al. NG-Tax, a highly accurate and
validated pipeline for analysis of 16S rRNA amplicons from complex biomes.
F1000Research. 2018;5:1791. https://doi.org/10.12688/f1000research.9227.2.
21. Delgado S, Florez AB, Mayo B. Antibiotic susceptibility of Lactobacillus and
Bifidobacterium species from the human gastrointestinal tract. Curr
Microbiol. 2005;50(4):202–7.
22. Moubareck C, Gavini F, Vaugien L, Butel MJ, Doucet-Populaire F. Antimicrobial
susceptibility of bifidobacteria. J Antimicrob Chemother. 2005;55(1):38–44.
23. Mangin I, Suau A, Gotteland M, Brunser O, Pochart P. Amoxicillin treatment
modifies the composition of Bifidobacterium species in infant intestinal
microbiota. Anaerobe. 2010;16(4):433–8.
24. Gilmore MS, Lebreton F, van Schaik W. Genomic transition of enterococci
from gut commensals to leading causes of multidrug-resistant hospital
infection in the antibiotic era. Curr Opin Microbiol. 2013;16(1):10–6.
25. Bizzarro MJ, Shabanova V, Baltimore RS, Dembry LM, Ehrenkranz RA,
Gallagher PG. Neonatal sepsis 2004-2013: the rise and fall of coagulase-
negative staphylococci. J Pediatr. 2015;166(5):1193–9.
26. Cortese F, Scicchitano P, Gesualdo M, Filaninno A, De Giorgi E, Schettini F,
et al. Early and late infections in newborns: where do we stand? A Review.
Pediatrics Neonatology. 2016;57(4):265–73.
27. Turroni F, Milani C, Duranti S, Ferrario C, Lugli GA, Mancabelli L, et al.
Bifidobacteria and the infant gut: an example of co-evolution and natural
selection. Cell Mol life Sci. 2018;75(1):103–18.
28. Ruiz L, Delgado S, Ruas-Madiedo P, Sanchez B, Margolles A. Bifidobacteria
and their molecular communication with the immune system. Front
Microbiol. 2017;8:2345.
29. O'Callaghan A, van Sinderen D. Bifidobacteria and their role as members of
the human gut microbiota. Front Microbiol. 2016;7:925.
30. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, et al.
Energy-balance studies reveal associations between gut microbes, caloric
load, and nutrient absorption in humans. Am J Clin Nutr. 2011;94(1):58–65.
31. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An
obesity-associated gut microbiome with increased capacity for energy
harvest. Nature. 2006;444(7122):1027–31.
32. Grier A, Qiu X, Bandyopadhyay S, Holden-Wiltse J, Kessler HA, Gill AL, et al.
Impact of prematurity and nutrition on the developing gut microbiome
and preterm infant growth. Microbiome. 2017;5(1):158.
Zwittink et al. BMC Pediatrics          (2020) 20:195 Page 9 of 10
33. Henderickx JGE, Zwittink RD, van Lingen RA, Knol J, Belzer C. The preterm
gut microbiota: an inconspicuous challenge in nutritional neonatal care.
Front Cell Infect Microbiol. 2019;9:85.
34. Markle JG, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-
Kampczyk U, et al. Sex differences in the gut microbiome drive hormone-
dependent regulation of autoimmunity. Science. 2013;339(6123):1084–8.
35. Mueller S, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T, et al. Differences
in fecal microbiota in different European study populations in relation to
age, gender, and country: a cross-sectional study. Appl Environ Microbiol.
2006;72(2):1027–33.
36. Martin R, Makino H, Cetinyurek Yavuz A, Ben-Amor K, Roelofs M, Ishikawa E,
et al. Early-life events, including mode of delivery and type of feeding,
siblings and gender, shape the developing gut microbiota. PLoS One. 2016;
11(6):e0158498.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Zwittink et al. BMC Pediatrics          (2020) 20:195 Page 10 of 10
